2228 — QuantumPharm Income Statement
0.000.00%
- HK$19.04bn
- HK$30.92bn
- CNY174.42m
Annual income statement for QuantumPharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 62.8 | 133 | 174 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 362 | 659 | 897 |
Operating Profit | -299 | -525 | -722 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -2,137 | -1,439 | -1,906 |
Provision for Income Taxes | |||
Net Income After Taxes | -2,137 | -1,439 | -1,906 |
Minority Interest | |||
Net Income Before Extraordinary Items | |||
Net Income | -2,137 | -1,439 | -1,914 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -2,137 | -1,439 | -1,914 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.627 | -0.422 | -0.581 |